Variation of tafamidis plasma levels during the treatment of TTR amyloidosis patients with Glu89Gln mutation.

Purpose: The transthyretin kinetic stabilizer tafamidis, used as a first-line therapy of amyloidosis patients, binds selectively to the transthyretin protein structure and thus prevents its dissociation. The limited information regarding tafamidis application in Glu89Gln amyloidosis patients imposed our research team to determine and evaluate its individual mean plasma levels and their biological variation.

Methods: The present cohort study investigated Bulgarian amyloidosis patients, grouped by gender, age, and therapy duration.

Exploring the Chemical Composition of Bulgarian Lavender Absolute ( Mill.) by GC/MS and GC-FID.

Lavender ( Mill.) is an important essential oil-bearing and medicinal plant with high commercial value. Lavender scent components can be derived not only as an essential oil but also as lavender concrete or absolute.

Determination of Tafamidis Plasma Concentrations in Amyloidosis Patients with Glu89Gln Mutation by HPLC-UV Detection.

Present study describes a high-performance liquid chromatography method for the determination of the potent kinetic stabilizer-Tafamidis in human plasma. It was approved for medical use in European Union in 2011. Ultra violet (UV) detection mode and isocratic elution of the mobile phase were set and made the analytical procedure fast and widely applicable.

Changes in gene expression of CXCR4, CCR7 and BCL2 after treatment of breast cancer cells with saponin extract from Tribulus terrestris.

Unlabelled: Saponins are natural substances produced by a large number of plants, one of which is Tribulus terrestris L. (TT). They have been reported to possess an antitumor activity exerted by regulating various signaling pathways in the cell.

Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status.

Promoter hypermethylation was shown to be involved in human cancerogenesis through silencing gene expression. Several studies were dedicated to explore the frequency and clinical significance of BRCA1 hypermethylation in sporadic breast cancer to identify a specific molecular and clinico-pathological phenotype. However the available data are limited and rather too heterogeneous.